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Purpose: Prolonged duration of cardiopulmonary bypass aggravates the degree of 
inflammation and coagulopathy. We investigated the influence of 6% hydroxyeth-
yl starch (HES) 130/0.4 on coagulation and inflammation compared with albumin 
when used for both cardiopulmonary bypass priming and perioperative fluid thera-
py in patients undergoing complex valvular heart surgery. Materials and Meth-
ods: Fifty four patients were randomly allocated into albumin-HES, albumin-non-
HES, and HES-HES groups. The cardiopulmonary bypass circuit was primed with 
5% albumin in the albumin-HES and albumin-nonHES group, and with HES in 
the HES-HES group. As perioperative fluid, only plasmalyte was used in the albu-
min-nonHES group whereas HES was used up to 20 mL/kg in the albumin-HES 
and albumin-HES group. Serial assessments of coagulation profiles using the rota-
tional thromboelastometry and inflammatory markers (tissue necrosis factor-α, in-
terleukin-6, and interleukin-8) were performed. Results: Patients’ characteristics 
and the duration of cardiopulmonary bypass (albumin-HES; 137±34 min, HES-
HES; 136±47 min, albumin-nonHES; 132±39 min) were all similar among the 
groups. Postoperative coagulation profiles demonstrated sporadic increases in clot 
formation time and coagulation time, without any differences in the actual amount 
of perioperative bleeding and transfusion requirements among the groups. Also, 
inflammatory markers showed significant activation after cardiopulmonary bypass 
without any differences among the groups. Conclusion: Even in the presence of 
prolonged duration of cardiopulmonary bypass, HES seemed to yield similar influ-
ence on the ensuing coagulopathy and inflammatory response when used for prim-
ing and perioperative fluid therapy following complex valvular heart surgery com-
pared with conventional fluid regimen including albumin and plasmalyte.
Key Words:   Blood coagulation, inflammation, cardiopulmonary bypass, cardiac 
surgical procedures
INTRODUCTION
To prime the cardiopulmonary bypass (CPB) circuit, various colloids are com-
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tall’s operation, combined valve and coronary artery bypass 
graft surgery or redo surgery) at the Cardiovascular Hospital 
of the Yonsei University Health System between June 2009 
and January 2011 were prospectively enrolled. Patients who 
had received heparin, Coumadin, or antiplatelet drugs within 
5 days before surgery were excluded from the study.
A computerized randomization table was used to assign 
the patients to one of the three groups (albumin-HES, HES-
HES, or albumin-nonHES) according to the priming solu-
tion preparation and perioperative fluid management strate-
gies. Regarding the priming solution, the CPB circuit was 
primed with 500 mL of 5% albumin and 1000 mL of plas-
malyte solution (Plasma Solution A Inj., CJ Pharma, Seoul, 
Korea) in the albumin-HES and albumin-nonHES group. 
In the HES-HES group, the circuit was primed with 500 
mL 6% HES 130/0.4 and 1000 mL of plasmalyte solution. 
Heparin (10 mg/L), sodium bicarbonate (40 mEq) and 20% 
mannitol (5 mL/kg) were added to the priming solution. A 
perfusionist who was not involved in the study prepared the 
priming solutions, and physicians were blinded to the ran-
domization results. Regarding the fluid management, in the 
albumin-HES and HES-HES group, up to 20 mL/kg of 6% 
HES 130/0.4 per day (including the volume used for prim-
ing) and plasmalyte solution were infused throughout the 
study period. In the albumin-nonHES group, only plasma-
lyte solution was infused. The infusion rate was adjusted to 
maintain the left ventricular end diastolic area, which was 
monitored with transesophageal echocardiography, within 
20% of the baseline, and to keep the cardiac index above 
2.0 L/min/m2 and urine output at more than 0.5 mL/kg/h 
during the surgery.
A standardized anesthetic and CPB management was 
provided to all patients. Anesthesia was induced with intra-
venous midazolam (0.03-0.05 mg/kg), sufentanil (1.5-2 
mcg/kg) and rocuronium (50 mg). Anesthesia was main-
tained with a continuous infusion of sufentanil (0.2-0.3 
mcg/kg/h), vecuronium (1-2 mcg/kg/min), and sevoflurane 
(0.6-2.0%) in 50% oxygen with air. Norepinephrine was in-
fused when the mean arterial pressure fell below 60 mm Hg. 
When the norepinephrine dose exceeded 0.3 μg/kg/min, va-
sopressin was added. Indications of milrinone infusion was 
when the cardiac index was below <2.0 L/min/m2 or when 
mixed venous oxygen saturation was below 60% despite 
optimization of preload and hematocrit. 
All patients were anticoagulated with heparin 300 units/
kg before CPB was established. Activated clotting time was 
measured every 30 min and kept above 480 sec during CPB 
monly used in addition to crystalloids in order to maintain 
the oncotic pressure and reduce fluid retention after CPB.1,2 
Among them, human albumin may be advantageous as it 
preserves the coagulation system3 and reduces inflammato-
ry response.4,5 However, its cost and potential to transmit 
infection limit the more widespread use of albumin.6
Six percent hydroxyethyl starch (HES) 130/0.4 (6% Volu-
ven Inj., Fresenius Kabi, Germany) is a synthetic colloid 
that has the advantage of a stronger plasma-expanding ef-
fect, an infrequent incidence of allergic reaction, and lower 
cost compared with albumin.7,8 As with other colloids, HES 
can produce dilutional coagulopathy and decrease factor 
VIII and von Willebrand factor levels. HES can also reduce 
the accessibility of glycoprotein IIb/IIIa on the surface of 
platelets. Nonetheless, due to a lower molecular weight and 
molar substitution ratio than its congeners, 6% HES 130/0.4 
has been shown to retain plasma-expanding effects with 
minimal influence on coagulation and higher plasma clear-
ance.9 In conjunction, HES 130/0.4 has been safely used in 
the cardiac surgical setting, even when used as a compo-
nent of the priming solution, without causing clinically sig-
nificant coagulopathy.9 
Inflammation is known to induce coagulopathy with a si-
multaneous suppression of the fibrinolytic system.10 In cas-
es of complex valvular heart surgery requiring prolonged 
duration of CPB, the negative influence of CPB-induced in-
flammation on the coagulation system is likely to be accen-
tuated resulting in a clinically significant coagulopathy, that 
may also be affected by the type of colloids used as a prim-
ing solution and/or perioperative fluid. Heretofore, the effi-
cacy of 6% HES 130/0.4 under these circumstances has not 
been validated.
In this randomised and controlled study, we compared the 
effects of 6% HES 130/0.4 with human albumin on coagu-
lation by using rotational thromboelastometry (ROTEM), 
and their effects on inflammation when used perioperative-
ly as a component of the priming solution in patients under-
going complex valvular heart surgery. 
MATERIALS AND METHODS
　　　
After Institutional Review Board approval and informed 
consent was obtained, 54 patients scheduled for complex 
cardiac surgery (combined mitral valve surgery and tricus-
pid annuloplasty, double-valve surgery, combined aortic 
valve replacement and ascending aorta replacement, Ben-
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same investigator who was unaware of the group assign-
ment. The measured ROTEM variables were: coagulation 
time, clot formation time, α angle, and maximum clot firm-
ness. Coagulation time represents the onset of coagulation, 
whereas the clot formation time and α-angle represent the 
initial rate of fibrin polymerization. Maximum clot firmness 
is a measurement of the maximal viscoelastic strength of the 
clot. ExTEM (tissue factor reagent) and InTEM (ellagic acid 
reagent) tests are indicated to evaluate platelet, plasma factor, 
and heparin. FibTEM (modified ExTEM test with cytochala-
sin D) is indicated to evaluate fibrinogen. Combination of 
ExTEM and FibTEM allows differential diagnosis of throm-
bocytopenia and/or hypofibrinogenemia within 20 min.12
Hemostatic variables
Hematocrit, platelet count, prothrombin time and activated 
partial thromboplastin time were measured before and 24 h 
after CPB. During the intraoperative period and postopera-
tive 24 h in the ICU, the amount of blood loss, urine output, 
fluid administered, and transfusion requirements were re-
corded. Intraoperative blood loss was recorded as the amount 
of reinfused salvaged blood by the cell salvage device. Post-
operative blood loss was recorded as the volume of chest 
tube drainage measured at 24 h after operation, which was 
not reinfused. 
Inflammatory markers
Blood samples for interleukin (IL)-6, IL-8, and tumor necro-
sis factor (TNF)-α were obtained from arterial blood before 
and 4, 12, and 24 h after CPB. The samples were placed in 
ice after collection and centrifuged immediately. Afterwards, 
the serum was separated and stored frozen at -70°C. Serum 
concentrations of TNF-α, IL-6, and IL-8 were assayed using 
enzyme-linked immunosorbent assay (Quantikine® high-
sensitive immunoassay; R&D Systems, Minneapolis, MN, 
USA). The assay has a detection limit of 0.038, 0.016, and 
1.5 pg/mL for TNF-α, IL-6, and IL-8, respectively. 
Statistical analysis
On the basis of an expected difference in postoperative max-
imum clot firmness according to a previous study,13 a sam-
ple size of 18 in each group was determined with a two-sid-
ed α level of 0.05 and a power of 0.8. 
Statistical analyses were performed with SPSS 15.0 (SPSS 
Inc., Chicago, IL, USA). Normality of distribution was as-
sessed with q-q plot and the Shapiro-Wilk test. Parametric 
data were analyzed using the analysis of variance for re-
with additional doses of heparin if required. CPB was per-
formed with non-pulsatile flow (2.2-2.4 L/min/m2) under 
α-stat management. Ultrafiltration was performed in all pa-
tients during CPB. To maintain the filling volume of the 
reservoir, plasmalyte solution was added. Packed red blood 
cells (pRBC) were added only when the patients’ hemato-
crit was less than 20% during CPB. Moderate hypothermia 
(33-34°C) and cold blood cardioplegia were used in all cas-
es. After CPB was terminated, heparin was neutralized with 
1 mg of protamine for each 100 units of the initial dose of 
heparin. Additional doses of protamine were given to achieve 
the pre-bypass activated clotting time. Additionally, blood 
from the CPB circuit was salvaged with a cell salvage de-
vice (Cell saver®, Haemonetic Corp, Braintree, MA, USA) 
and retransfused after sternal closure. After surgery, all pa-
tients were transferred to the intensive care unit (ICU), where 
pRBC were transfused when hematocrit was lower than 
25%. Fresh frozen plasma (FFP) was transfused when the 
international normalized ratio was above 1.5 with bleeding 
greater than 200 mL/h for 2 consecutive hours after opera-
tion. Platelet concentrates were transfused when a platelet 
count was less than 50000/μL with excessive bleeding 
greater than 200 mL/h for 2 consecutive hours after opera-
tion. Surgical re-exploration was indicated when bleeding 
was >200 mL/h for 6 consecutive hours or >400 mL during 
the first hour postoperatively, despite a normal active clot-
ting time (ACT) and global coagulation status. 
Cardiac index, heart rate, mean arterial blood pressure, 
central venous pressure, pulmonary arterial pressure, and 
pulmonary artery occlusion pressure were checked 10 min 
after induction, 10 min after weaning from CPB, 10 min after 
pericardial closure, and 1 h, 12 h, and 24 h after the opera-
tion. In the postoperative period, the incidence of acute kid-
ney injury according to the risk, injury, failure, loss and end-
stage kidney (RIFLE) criteria,11 the length of stay in the ICU, 
and length of postoperative hospitalization were also record-
ed. Physicians who were blinded to the studies directed post-
operative management and collected data for all the patients.
Rotational thromboelastometry (ROTEM®, 
PentapharmGmBh, Munich, Germany) tracing
Blood samples for ROTEM tracing were obtained via a radi-
al artery catheter into polypropylene tubes (BD Vacutainer®, 
BD Diagnostics, Plymouth, UK) containing 3.2% buffered 
citrate before and 24 h after CPB. ROTEM using 3 activators 
[intrinsic ROTEM (InTEM®); extrinsic ROTEM (ExTEM®); 
and fibrinogen ROTEM (FibTEM®)] was performed by the 
Jang-Eun Cho, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014628
up to 24 h after the surgery was significantly decreased com-
pared to each corresponding baseline value (data not shown). 
ROTEM variables were similar among the groups before 
and after CPB (Table 2). InTEM, clot formation time in-
creased after CPB in the albumin-HES and albumin-non-
HES group. Furthermore, maximum clot firmness inTEM 
decreased significantly in all groups after CPB. In the albu-
min-non HES group, ExTEM clot formation time increased 
and maximum clot firmness reduced, and FibTEM coagu-
lation time increased significantly after CPB. In the albu-
min-HES and HES-HES groups, ExTEM and FibTEM 
variables remained unchanged after CPB (Table 2). 
Perioperative hematologic variables, including the rou-
tine coagulation tests, the actual amount of bleeding, and 
transfusion requirements, were all comparable among the 
groups. Perioperative fluid balance was also similar among 
the groups with no patients requiring hemostatic re-explo-
ration (Table 3).
Postoperative data, including the incidence of acute kid-
ney injury, lengths of stay in the ICU and hospital, and mor-
tality rate, were all similar among the groups (Table 4). No 
patients required postoperative renal replacement therapy. 
peated measurements followed by post hoc Dunnett’s test. 
Non-parametric data were compared using the Kruskall-
Wallis and Friedman tests among and within the groups, re-
spectively. After the Kruskall-Wallis test, the Mann-Whit-
ney U test was applied to analyze difference between the 
two groups. The Wilcoxon test was used for paired compar-
isons. Frequencies were evaluated by chi-squared test and 
Fisher’s exact test. All values were expressed as median 
[interquartile range], mean±standard deviation, or the num-
ber of patients. In figures, inflammatory cytokines were ex-
pressed as median (min, max). A p-value of <0.05 was con-
sidered to be statistically significant. 
 
RESULTS
 
Patients’ characteristics, EuroSCORE, and operative data in-
cluding the duration of CPB and the amount of ultrafiltration 
during CPB were all similar among the groups (Table 1). 
There were no significant differences in the perioperative 
hemodynamic variables among the groups throughout the 
study period. In all groups, mean pulmonary arterial pressure 
Table 1. Patients’ Characteristics
HA-HES group (n=18) HES-HES group (n=18) HA-nonHES group (n=18) p value
Age (yrs)   62±11   64±13   57±17 0.324
Gender (male/female) 6/12 7/11 7/11 0.923
BMI (kg/m2) 23.4±3.0 23.7±3.9 22.6±3.4 0.652
Diabetes mellitus (n)   2   3   2 1.000
Hypertension (n)   5   7   5 1.000
Pre-operative LVEF (%) 67±7   56±15   61±16 0.068
Preoperative medications (n)
    β-blockers   4   5   3 0.624
    Calcium channel blockers   4   4   3 0.682
    Renin angiotensin system inhibitors   6   9   8 0.504
    Digoxin   5   4   8 0.336
    Diuretics 10 12 13 0.300
Type of surgical procedures (n) 0.110
    MVR+TAP   5   2   4
    DVR   6   3   6
    AVR+ascending aorta replacement   4   8   3
    Bentall’s operation   2   2   3
    Valve+CABG   1   3   2
Redo operation   2   4   2 0.516
EuroSCORE 2 [1-5] 3 [2-4] 2 [1-3] 0.403
Duration of ACC (min) 110±26 104±44 100±32 0.681
Duration of CPB (min) 137±34 136±47 132±39 0.918
HA, 5% human albumin; HES, 6% hydroxyethyl starch 130/0.4; BMI, body mass index; LVEF, left ventricular ejection fraction; EuroSCORE, European Sys-
tem for Cardiac Operative Risk Evaluation; AVR, aortic valve replacement; MVR, mitral valve replacement; TAP, tricuspid annuloplasty; DVR, double valve 
replacement; CABG, coronary artery bypass graft; ACC, aortic cross clamp; CPB, cardiopulmonary bypass.
Values are number of patients or mean±standard deviation or median [interquartile range].
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min when used for both CPB priming and perioperative flu-
id therapy in patients undergoing complex valvular heart 
surgery. No significant differences were noted based on the 
type of colloid used. Postoperative coagulation profiles eval-
uated with ROTEM demonstrated sporadic increases in clot 
formation time and coagulation time, without any differenc-
es in the actual amount of perioperative bleeding or transfu-
sion requirements among the groups. Also, inflammatory 
markers showed significant activation after CPB without any 
differences among the groups. 
Compared with its congeners, the lower molecular weight 
of 6% HES 130/0.4 (mean molecular weight: 130 kDa; de-
gree of substitution: 0.4) has been shown to be associated 
with minimal coagulation disturbance,7-9 while the lower 
There were no significant differences in the serum con-
centrations of inflammatory markers among the groups 
throughout the study period. TNF-α, IL-6, and IL-8 were 
significantly increased in all groups throughout the postop-
erative period compared to their corresponding baseline val-
ues. TNF-α and IL-8 in all groups were highest 4 hours af-
ter CPB and decreased as time passed. IL-6 was highest 4 
and 12 hours after CPB in all groups (Fig. 1). 
DISCUSSION
This study evaluated the influence of 6% HES 130/0.4 on 
coagulation and inflammation, compared with human albu-
Table 2. ROTEM before [Pre] and 24 h after [Post] CPB
HA-HES HES-HES HA-nonHES p value
InTEM
    Coagulation time (s)
        PreCPB 187 [173-224] 204 [148-289] 200 [172-271] 0.75
        PostCPB 242 [187-268] 228 [162-283] 274 [219-344] 0.428
    Clot formation time (s)
   PreCPB   91 [75-114]   88 [71-132]   70 [68-92] 0.124
   PostCPB 115 [92-193]* 121 [80-208] 119 [101-138]* 0.972
    α angle (°)
        PreCPB   73 [68-75]   73 [69-76]   76 [73-77] 0.109
        PostCPB   72 [61-73]   70 [54-76]   69 [65-71]* 0.977
    Maximum clot firmness (mm)
        PreCPB   60 [57-64]   63 [58-65]   61 [56-65] 0.602
        PostCPB   54 [45-58]*   52 [45-56]*   57 [51-59]* 0.085
ExTEM
    Coagulation time (s) 
        PreCPB   57 [49-75]   55 [49-67]   50 [45-52] 0.123
        PostCPB   58 [50-80]   55 [45-70]   52 [45-60] 0.234
    Clot formation time (s)
        PreCPB 104 [79-124]   99 [82-112]   85 [73-112] 0.514
        PostCPB 114 [106-165] 105 [86-144] 120 [93-126]* 0.482
    α angle (°)
        PreCPB   71 [65-74]   72 [68-74]   74 [71-78] 0.130
        PostCPB   69 [64-72]   72 [67-76]   74 [70-76] 0.093
    Maximum clot firmness (mm)
        PreCPB   59 [54-61]   63 [58-65]   62 [57-66] 0.057
        PostCPB   56 [50-62]   59 [56-63]   58 [55-61]* 0.314
FibTEM
    Maximum clot firmness (mm)
        PreCPB   14 [11-17]   17 [14-25]   18 [15-20] 0.052
        PostCPB   16 [13-20]   17 [11-20]   18 [15-25] 0.658
preCPB, before cardiopulmonary bypass; postCPB, after cardiopulmonary bypass; ROTEM, rotation thromboelastography; HA, 5% human albumin; HES, 6% 
hydroxyethyl starch 130/0.4; InTEM, intrinsic ROTEM; ExTEM, extrinsic ROTEM; FibTEM, fibrinogen ROTEM.
Values are median [interquartile range].
*p<0.05 between pre- and postCPB within group.
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Table 3. Blood Loss, Transfusion Requirement, Coagulation Variables, and Fluid Balance
Intraoperative Postoperative 24 h
Blood loss (mL)
    HA-HES    500 [480-720]     450 [380-740]
    HES-HES    583 [420-700]       495 [410-1220]
    HA-nonHES    500 [485-665]     430 [280-685]
Transfused pRBC (units)/patients number (%)
    HA-HES             1 [0-1]/10 (56)           0 [0-1]/8 (44)
    HES-HES             1 [0-2]/11 (61)              0 [0-1.5]/8 (44)
    HA-nonHES           0 [0-1]/7 (39)           0 [0-1]/7 (39)
Transfused FFP (units)/patients number (%)
    HA-HES          0 [0-3]/5 (28)           0 [0-0]/3 (17)
    HES-HES          0 [0-3]/5 (28)              0 [0-0.5]/4 (22)
    HA-nonHES          0 [0-3]/5 (28)           0 [0-0]/3 (17)
Transfused Plts (units)/patients number (%)
    HA-HES          0 [0-0]/2 (11)         0 [0-0]/1 (6)
    HES-HES           0 [0-0]/3 (17)         0 [0-0]/1 (6)
    HA-nonHES         0 [0-0]/1 (6)           0 [0-0]/2 (11)
Hematocrit (%)
    HA-HES 36±6 27±2
    HES-HES 36±6 29±4
    HA-nonHES 36±4 30±3
Platelet count (109·l-1)
    HA-HES 226±50   93±23
    HES-HES 213±61 100±14
    HA-nonHES 188±58 103±29
PT (s)
    HA-HES 12.8±3.0 14.1±1.9
    HES-HES 13.7±5.6 13.6±1.3
    HA-nonHES 13.8±3.3 14.1±1.9
aPTT (s)
    HA-HES   36.5±12.4 34.1±7.3
    HES-HES   35.4±11.0   36.5±19.3
    HA-nonHES   36.2±14.7   33.9±12.8
HES (mL)
    HA-HES      650 [500-1000]     550 [215-783]
    HES-HES      1000 [1000-1400]     500 [200-800]
    HA-nonHES  0 [0-0]*   0 [0-0]*
HA (mL)
    HA-HES    500 [500-500] 0 [0-0]
    HES-HES 0 [0-0]† 0 [0-0]
    HA-nonHES    500 [500-500] 0 [0-0]
Plasmalyte solution (mL)
    HA-HES      3000 [2450-3400]       3758 [2728-4665]
    HES-HES      2498 [1953-2600]       3537 [3040-4341]
    HA-nonHES      2403 [2055-3415]       3295 [2657-3933]
HA, 5% human albumin; HES, 6% hydroxyethyl starch 130/0.4; pRBC, packed red blood cells; FFP, fresh frozen plasma; Plt, platelet concentrations; PT, 
prothrombin time; aPTT, activated partial thromboplastin time. 
Values are median [interquartile range] or mean±standard deviation or number of patients. Total, combined data of intraoperative and postoperative 24 h. 
*p<0.005 compared with HA-HES and HES-HES group. 
†p<0.005 compared with HA-HES and HA-nonHES group.
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Table 4. Postoperative Datas
HA-HES (n=18) HES-HES (n=18) HA-nonHES (n=18) p value
Hemofiltration (mL) 1200 [800-1875] 1000 [850-2200] 1000 [100-1650] 0.417
AKI (n) 4 4 5 0.629
ICU day (day)   3.3±0.9   3.2±1.0   2.7±0.9 0.196
Hospital day (day) 13.2±4.4 11.2±5.5 12.4±3.4 0.671
Mortality (n) 0 1 0 0.981
HA, 5% human albumin; HES, 6% hydroxyethyl starch 130/0.4; AKI, acute kidney injury by RIFLE (R-risk, I-injury, F-failure, LE-loss and end stage renal dis-
ease) criteria; ICU, intensive care unit.
Values are number of patients or median [interquartile range].
Fig. 1. Changes in inflammatory cytokines. (A) TNF-α, (B) IL-6, (C) IL-8. Data are expressed as median (maximum, minimum). *p<0.05, 
†p<0.005 compared with preCPB within group. HA, 5% human albumin; HES, 6% hydroxyethyl starch 130/0.4; CPB, cardiopulmonary by-
pass; TNF, tumor necrosis factor; IL, interleukin. 
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tests, we could observe neither any differences among the 
groups nor within each group before and after CPB. Al-
though CPB is known to exert adverse influence on the co-
agulation system, these findings are not surprising, since 
patients were transfused with FFP or platelet concentrates 
according to the results of these tests.
In contrast, a certain degree of sporadic deterioration of 
the coagulation system after CPB could be detected by 
ROTEM analysis without differences among the groups. 
ROTEM technology has the advantage of quickly provid-
ing a global assessment of coagulopathy, compared with the 
routine coagulation tests.26-29 As our results indicate, no sig-
nificant differences could be noted in the assessed ROTEM 
parameters among the groups despite sporadic deterioration 
of the coagulation system after CPB. In conjunction, no dif-
ferences were noted in the actual amount of perioperative 
bleeding and transfusion requirement, confirming the safety 
of 6% HES 130/0.4 when used for priming and periopera-
tive fluid therapy. The safety of 6% HES 130/0.4, com-
pared to human albumin, is further confirmed by the find-
ings that no differences could be noted when comparing 
with the albumin-nonHES group, in which HES was not 
administered at all.
As for the inflammation, we could observe a universal in-
crease of the assessed markers, which peaked at 4 hours af-
ter CPB, as expected. However, as with ROTEM parameters, 
we could not observe any significant differences according to 
the type of colloid used. The inflammatory cytokines, in-
cluding TNF-α, IL-6, and IL-8, have been shown to corre-
late with the severity of tissue damage induced by surgery 
and the inflammatory response to CPB.30 Although albumin 
has been shown to modulate the ensuing CPB-related in-
flammation, evidence on the influence of other priming col-
loids on the inflammatory response is limited and inconclu-
sive. As we could not observe any differences in the assessed 
inflammatory markers even in the albumin-nonHES group, 
the choice of priming solution and perioperative fluid does 
not seem to affect the inflammatory response following car-
diac surgery using CPB.
Although not the primary endpoint of this study, we as-
sessed the incidence of acute kidney injury, as concerns 
have been raised in recent literature on a potential adverse 
influence of HES solution on the renal function.31,32 In con-
trast to those previous studies, we did not observe any neg-
ative effects of HES on the kidney when compared with al-
bumin and plasmalyte solution, which may be attributable 
to the different patient population, type of HES solution 
molecular substitution ratio has been shown to result in rap-
id total body clearance, potentially exerting less renal toxic-
ity.14 Nevertheless, concerns remain about the adverse ef-
fects of HES on hemostasis, especially in the cardiac surgical 
setting. HES may interfere with coagulation through reduc-
tions in factor VIII, von Willebrand factor, platelets, func-
tional impairment of platelets, and enhancement of fibrino-
lysis.15 However, some investigations have demonstrated 
that HES itself is not associated with clinically significant 
bleeding in defiance of its possible association with sub-
clinical alterations of the coagulation system.16 
CPB induces hemodilution, activation of the coagulation 
system, and fibrinolysis that negatively affects hemosta-
sis.1,17 Moreover, several studies have reported positive cor-
relations between CPB duration and a negative influence on 
coagulation variables such as increased thrombin inhibition 
and fibrinolysis.18 Indeed, coagulopathy and increased bleed-
ing are serious complications, particularly occurring after 
prolonged CPB,19,20 which is also associated with an in-
creased risk of morbidity and mortality.21,22 Yet, the safety 
and efficacy of 6% HES 130/0.4 in complex valvular heart 
surgery, in which prolonged duration of CPB is expected, 
remain elusive. Although the safety of 6% HES 130/0.4 as 
a component of the priming solution, compared with hu-
man albumin in terms of coagulation and inflammation, has 
been demonstrated in a recent study, that study was per-
formed in patients undergoing simple mitral valvular sur-
gery with a mean CPB duration of 1 h.23 Moreover, no com-
prehensive data exist regarding the influence of 6% HES 
130/0.4 on coagulation and inflammation when used as a 
perioperative fluid regimen.
In contrast to HES, albumin per se has no adverse influ-
ence on the coagulation system. The only adverse influence 
of human albumin on coagulation seems to stem from its 
subsequent hemodilutional effect.2-4 Furthermore, when 
used for priming, albumin forms a layer on the surface of 
the CPB circuit, making it less thrombogenic, which de-
creases the affinity of the platelets, leading to their preserva-
tion.24 In terms of inflammation, albumin has been shown to 
inhibit apoptosis5 and attenuate the inflammatory response.25 
Nevertheless, its high cost and the possibility to transmit in-
fection cannot be ignored.
In the current trial, perioperative use of up to 20 mL/kg 
6% HES 130/0.4 for priming as well as perioperative fluid 
management yielded similar safety and efficacy results in 
terms of coagulation and inflammation when compared 
against human albumin. Regarding the routine coagulation 
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et al. Transfusion-related acute lung injury in cardiac surgery pa-
tients is characterized by pulmonary inflammation and coagulopa-
thy: a prospective nested case-control study. Crit Care Med 
2012;40:2813-20.
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impair blood coagulation after cardiac surgery: a prospective ran-
domized trial. Anesth Analg 2009;108:30-6.
14. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet 
B, Van Aken H. Hydroxyethyl starches: different products--differ-
ent effects. Anesthesiology 2009;111:187-202. 
15. Kuitunen AH, Hynynen MJ, Vahtera E, Salmenperä MT. Hy-
droxyethyl starch as a priming solution for cardiopulmonary by-
pass impairs hemostasis after cardiac surgery. Anesth Analg 
2004;98:291-7.
16. Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt 
MT, et al. Fluid resuscitation in circulatory shock: a comparison of 
the cardiorespiratory effects of albumin, hetastarch, and saline so-
lutions in patients with hypovolemic and septic shock. Crit Care 
Med 1983;11:839-50.
17. Niemi TT, Kuitunen AH. Artificial colloids impair haemostasis. 
An in vitro study using thromboelastometry coagulation analysis. 
Acta Anaesthesiol Scand 2005;49:373-8.
18. Nakahira A, Sasaki Y, Hirai H, Fukui T, Matsuo M, Takahashi Y, 
et al. Closed cardiopulmonary bypass circuits suppress thrombin 
generation during coronary artery bypass grafting. Interact Cardio-
vasc Thorac Surg 2010;10:555-60. 
19. Karkouti K, McCluskey SA, Syed S, Pazaratz C, Poonawala H, 
Crowther MA. The influence of perioperative coagulation status 
(10% versus 6%) and the total allowable volume of HES.31,32 
Nonetheless, it is beyond the scope of this study to validate 
the renal safety of 6% HES 130/0.4 as this study is not suf-
ficiently powered to draw any conclusion in that regard, 
which merits further studies. 
The limitations of this study are as follows. First, as we 
calculated the sample size on the basis of the previous study 
to address a difference in ROTEM variables, it is difficult 
to extrapolate the effects of different priming solutions and 
perioperative fluids on the actual clinical endpoints from 
the current small scale and a single-center study. Second, 
intraoperative blood loss during cardiac surgery is difficult 
to accurately assess. Although we had used the intraopera-
tively processed volume by a cell salvage device as a surro-
gate marker, actual amount of intraoperative blood loss may 
have been different. Third, ROTEM was performed 24 hours 
after CPB. The reason we did not perform the ROTEM anal-
ysis at the end of the surgery was that coagulation at this 
time point could be influenced by many factors including 
residual hemodilution, excess free water and heparin re-
bound. Although data at various time points postoperatively 
could be missed, sporadic deterioration of the coagulation 
system could still be depicted by ROTEM analysis 24 h af-
ter CPB as observed in the current study.
In conclusion, 6% HES 130/0.4, when used for priming 
and perioperative fluid therapy up to 20 mL/kg, seemed to 
yield similar influence on the ensuing coagulopathy and in-
flammatory response following complex valvular heart sur-
gery requiring prolonged duration of CPB, compared with 
conventional fluid regimen including albumin and plasmalyte. 
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